Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's strong financial position is underscored by approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables as of the end of Q3 2025, positioning the company well for future investments and developments. The company's transition towards becoming a fully integrated oncology company, coupled with an array of diverse pipeline catalysts projected for 2026, presents significant potential for upside opportunities. Additionally, promising data from clinical trials, particularly regarding the effectiveness of BioNTech's therapies, strengthens the outlook for the company's ability to sustain growth and deliver value to shareholders despite declines in COVID-19 vaccine revenues.

Bears say

BioNTech is facing a sustained decline in COVID-related revenues, with projections indicating an 18% decrease in 2025 and a further reduction anticipated in subsequent years, which may hinder cash flow for ongoing R&D initiatives. Manufacturing challenges related to personalized therapeutics, characterized by longer production cycles, may limit the company's ability to capitalize on anticipated cancer therapies. Furthermore, the company presents multiple risks, including potential negative data from their pipeline candidates and various operational uncertainties, collectively contributing to a negative outlook on future revenue generation.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.